News & Updates
Showing Oncology articles
Showing
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
20 Jan 2023
TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.
TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
20 Jan 2023
POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC
POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC
20 Jan 2023
MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.
MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
19 Jan 2023
START-FIT: TACE + RT + avelumab promising as conversion therapy for locally advanced unresectable HCC
START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.
